ALKEM.NS Profit & Loss
Alkem Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹115.99 Bn | ₹126.68 Bn | ₹129.65 Bn | ₹147.12 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹2.16 Bn | ₹3.11 Bn | ₹4.94 Bn | ₹5.83 Bn | OtherIncome |
| Total Income | ₹118.15 Bn | ₹129.78 Bn | ₹134.58 Bn | ₹152.96 Bn | Income |
| Cost of Materials Consumed | ₹30.57 Bn | ₹32.95 Bn | ₹34.40 Bn | ₹35.65 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹13.88 Bn | ₹16.29 Bn | ₹15.14 Bn | ₹16.95 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹4.62 Bn | ₹0.14 Bn | ₹-1.90 Bn | ₹-1.67 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹21.31 Bn | ₹22.01 Bn | ₹24.54 Bn | ₹28.37 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹1.07 Bn | ₹1.12 Bn | ₹1.22 Bn | ₹1.61 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹3.10 Bn | ₹2.99 Bn | ₹3.57 Bn | ₹3.82 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹29.52 Bn | ₹32.84 Bn | ₹32.34 Bn | ₹37.77 Bn | OtherExpenses |
| Total Expenses | ₹104.08 Bn | ₹108.34 Bn | ₹109.31 Bn | ₹122.50 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹14.08 Bn | ₹21.45 Bn | ₹25.27 Bn | ₹30.46 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-1.03 Bn | ₹-1.21 Bn | ₹0.00 Bn | ₹-1.75 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹13.05 Bn | ₹20.23 Bn | ₹25.27 Bn | ₹28.71 Bn | ProfitBeforeTax |
| Tax Expense | ₹2.98 Bn | ₹2.12 Bn | ₹3.11 Bn | ₹5.18 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹10.07 Bn | ₹18.11 Bn | ₹22.15 Bn | ₹23.51 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹9.84 Bn | ₹17.96 Bn | ₹21.65 Bn | ₹23.02 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹82.31 | ₹150.19 | ₹181.11 | ₹192.51 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹82.31 | ₹150.19 | ₹181.11 | ₹192.51 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from ALKEM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).